GYRE earnings date and last-quarter result: next report 2026-08-10, last quarter beat, P/E -80.38. Updated 2026-07-23.
Gyre Therapeutics (GYRE) Research Hub
Gyre Therapeutics (GYRE) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 6.07 USD (+3.76%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -80.38, market cap 0.54B. This hub links to the full technical, earnings and options research available for GYRE.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 6.07 USD (+3.76%) |
| 52-week range | 5.62 USD – 7.74 USD |
| Trend regime | Range |
| 14-day RSI | 26.9 (Oversold) |
| Trailing P/E | -80.38 |
| Market cap | 0.54B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-10 |
Available research for GYRE
Covered Call on GYRE: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GYRE: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GYRE: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
GYRE technical analysis: range, last 6.07 USD, RSI 26.9, 52w range 5.62 USD–7.74 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is GYRE in?
Gyre Therapeutics (GYRE) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is GYRE in an uptrend or downtrend?
As of 2026-10-26, GYRE is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GYRE's trailing P/E ratio?
GYRE's trailing P/E is -80.38, with a market cap of 0.54B. See the earnings research page for full valuation detail.
When does GYRE next report earnings?
GYRE is next scheduled to report earnings on 2026-08-10.